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Abstract
The world is experiencing an increase in chronic diseases like diabetes, inflam-
matory bowel diseases, cancer, cardiovascular diseases, obesity, and diabetes pre-
ceding disease like gestational diabetes. Most of these diseases can be prevented and 
mitigated if individuals pay attention to the causative factors. One of such factors 
is the type of microorganisms in an individual’s gut. Even though there are innate 
beneficial microorganisms in the human gut, pathogenic microorganisms can 
invade the gut, changing the inborn population of the gut microbiota. The changes 
in the gut microbiota population have been linked to several diseases. This chapter, 
therefore, describes gut microbiota and their interaction with specific diseases. Also 
discussed in this chapter are the changes to gut microbiota composition that pose a 
risk to the host. There is substantial evidence that diseases are initiated or worsened 
with a change in the gut microbiota composition. Therefore, the gut microbiota 
plays a crucial role in individuals’ health and requires human efforts to keep them 
in the right population. Furthermore, making lifestyle changes, particularly food 
choices and behaviors such as the misuse of medications and excessive alcohol 
consumption, should be monitored and controlled to support gut health.
Keywords: Gut microbiota, Bacteria phylum, Gestational diabetes, Chronic diseases, 
Gut dysbiosis
1. Introduction
Chronic diseases (CD) are unfavorable health statuses lasting for over one year 
or more [1, 2]. Such diseases require continual medical attention and activities 
that could mitigate the severity [1, 2]. The diseases are the leading cause of death 
and incapacity worldwide, with influences on all socio-economic setups. In 2002, 
the CD was reported as the cause of 60% of death and 43% global distress [1, 3]. 
In 2020, the cause of death through CD had risen to 73% and universal distress of 
60%, as shown in Figure 1 [3]. The cause of some of these diseases was attributed 
to different factors such as genes, poor diet, and lifestyle [1, 4]. The common CD 
includes diabetes, cancer, cardiovascular diseases, chronic pulmonary diseases, obe-
sity, arthritis, stroke, Alzheimer’s diseases, chronic kidney diseases, inflammatory 
bowel diseases, tooth decay, and epilepsy [1, 3, 5]. Some diseases are signals to the 
potential development of chronic diseases. Women who have gestational diabetes 
are at risk of developing type 2 diabetes, hypertension, cardiovascular diseases, and 
obesity, just as high blood cholesterol could be indicative of future coronary heart 
diseases, obesity, and hypertension [6, 7].
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Asides from death and health difficulties associated with CD, there are several 
negative impacts socially and economically. The family of people suffering from 
one or more CD reported increased personal life burden, financial difficulties, 
impaired social relations, and intrinsic rewards [8, 9]. Likewise, treating CD and 
helping people with such diseases significantly impact different countries’ finances. 
It has become a substantial financial burden to nations [10, 11]. In the United States 
of America, $327 billion is spent annually on medical costs for diabetes [5]. About 
$147 billion per year for the health cost of obesity, $164 billion for arthritis, $500 
billion for Alzheimer’s diseases, epilepsy takes $8.6 billion annually, and $45 billion 
is spent on annual health care for tooth decay [5]. In 2015, a forecasted percentage 
of Gross Domestic Product (GDP) loss was reported for different countries world-
wide. Brazil was expected to lose 3.21% of GDP, Canada, 0.64%, China, 3.94%, 
India, 5.05%, Nigeria, 3.07%, Russia, 12.35%, Tanzania, 4.19%, United Kingdom, 
5.18% GDP losses from death caused by diseases. In another report, the United 
States loses $1.1trillion annually from the lack of productivity of citizens living with 
CD. Reducing the rate of obesity alone in the country would increase productivity 
by $254 billion and $60 billion in reductions in treatment costs [10, 11].
With the national, family, and personal losses associated with CD, methods of 
curbing the rising rate call for more research, government and non-governmental 
initiatives, and policies [10]. One research aspect was to figure out the genesis of all 
these diseases [4, 12]. From different findings, diverse components contribute to the 
incidence of diseases or increase the risks of developing these diseases. For example, 
the cause of some of these diseases was attributed to individual genes, other influences 
such as unhealthy diet, overweight, sedentary lifestyle (lack of physical activities), and 
risk behaviors such as tobacco use and excessive alcohol were identified. One crucial 
discovery on factors contributing to disease incidence was the gut microbiota [13–15].
2. The gut microbiota
The human body consists of several microorganisms which were innately ben-
eficial to the host. These colonies of microorganisms that have settled in the human’s 
gastrointestinal tract (GIT, gut) over many years include bacteria, eukaryotes, bacte-
riophages, archaea, and fungi, and they are called the gut microbiota (GM) [13, 16]. 
The GM has evolved and established a commensal relationship with the human host 
Figure 1. 
Chart showing the rate of increase in death and distress as caused by chronic diseases.
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over many years. Hence, they are equally referred to as commensals microorganisms 
because they provide health benefits to the host while the commensals get nutrients 
from the host without harming the host [13, 16].
There are trillions of microorganisms colonizing humans, but research focuses 
on the bacteria community [17, 18]. Some years ago, scientists reported that the bac-
teria cells in the GIT are numerous, much more than the number of cells in the body. 
Some other researchers claimed that the bacterial cells in the GIT are ten times more 
than body cells [13, 19]. Recent studies, however, showed human cells and bacterial 
cells are at a ratio of 1:1 [13, 19, 20].
Humans’ GM is developed from birth [19, 21, 22]. Particularly for babies deliv-
ered vaginally, the microbiota in the mother’s cervix is passed on to the babies. 
This GM received from birth builds the first wall of defense in children, and the 
population of GM gradually changes as the child grows. In addition, gut bacteria aid 
adaptive immunity, a crucial function of the GM in the human’s body [13, 21, 22].
2.1 Functions of gut microbiota
The GM proffer benefits to the host. The first known function is to assist in 
building immunity after birth. The GM has other functions in the body; they 
contribute advantages anatomically, physiologically, and immunologically [19, 23].
2.1.1 Anatomical and physiological functions
The GM is known for the breakdown of carbohydrates, particularly the indigest-
ible dietary fibers, like cellulose, resistant starch, pectin, oat, wheat bran, and inulin 
[24, 25]. The absorption of nutrients from dietary fiber has been associated with 
satiety feeling after eating, thus preventing overeating. The GM metabolizes protein 
by the secretion of digestive enzymes. Synthesis of vitamin K and B vitamins such 
as vitamin B12, riboflavin, niacin, and folate, and other digestive enzymes are also 
performed by GM [23, 24]. The GM also performs physiological benefits of strength-
ening the gut, shaping the intestinal epithelium, and harvesting energy [13].
Anatomically, the GM assists in maintaining the mucosal barrier’s strength by 
shaping the intestinal epithelium, thereby sustaining gut integrity. Furthermore, 
the metabolites produced during the breakdown of dietary fibers are absorbed 
by the epithelial cells to assist cell proliferation, differentiation, and apoptosis of 
harmful cells, like the cancer cells [23, 26]. The GM is sometimes called the second 
brain because of its effect on the brain. This is because the metabolites released 
during the breakdown of fibers are absorbed to support brain activities [19, 27].
2.1.2 Immunological functions
The GM provides immunity to the host by building colonization resistance, a 
situation in which the innate GM antagonizes foreign microorganisms’ colonization 
and prompts the preservation of structural and functional protective mucosal bar-
riers [14, 15]. The GM in humans also invades and takeover foreign pathogens in the 
gut [19, 21]. The metabolites produced by GM, the short-chain fatty acids (SCFAs), 
reduces the intestinal pH, thus making survival difficult for foreign microorgan-
isms [14, 15]. The functions of SCFAs will be discussed in subsequent sections of 
this chapter. In addition, the GM improves the integrity of intestinal mucosal to 
prevent invasion by foreign organisms. Another function of GM is the metabolism 
of xenobiotics [14, 15]. Xenobiotics, which are foreign materials to the bodies’ biol-
ogy, include drugs or chemicals that could be toxic [15]. Thus, the GM prevents the 
body from toxins by breaking them down from their harmful state.
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2.2 The pathogenicity of the gut microbiota
Even though gut bacteria are beneficial, they could become pathogenic in their 
interaction with changes in the host environment and vectors. For example, if 
microorganisms giving benefits to the host invades other sites they do not usually 
colonize, that change in their environment could result in them acting as pathogens 
which could cause diseases [28, 29]. Furthermore, microorganisms in the body can 
also contribute to polymicrobial infections. Polymicrobial infection occurs when 
different microorganisms in the body interact and cooperate to create diseases in the 
host [28, 29]. Therefore, treatment has to be offered to take care of all microorganisms 
contributing to the infection.
One salient way the GM becomes harmful to the body is if its population in the 
gut undergoes unusual changes due to drug use, aging, sicknesses, lifestyle, and 
unhealthy food choices. This abnormal change in the population can result in gut 
dysbiosis (GD), which would be discussed in the subsequent section. In addition, 
changes to GM populations have been related to autoimmune situations, aller-
gies, and chronic diseases. The incidence of diseases like autism, asthma, colitis, 
obesity, gestational diabetes, type 1 & 2 diabetes has been linked to GM’s activity 
in its natural state or an altered nature [19]. Studies have equally shown a disparity 
in the types of GM or their populations present in a healthy and sick adult. For 
example, the type and population of GM in people living with gestational diabetes 
and type 2 diabetes differs from individuals free from the disease [24, 30]. The 
composition and population of the GM are identified to be influenced by factors 
such as diet, feeding type, birth delivery mode, and age of hosts [30, 31].
3. Phylum of gut bacteria in human body
Researchers identified the prominent type of GM colonizing the human gut, 
which is bacteria; therefore, subsequent sections of this chapter will focus on gut 
bacteria. Recently, scientists compiled data that shows there are about 2172 species 
of microorganisms isolated from humans. These species were classified into 12 
phyla. The predominant phyla that make up about 93.5% of humans’ colonies are 
bacteria, Proteobacteria, Actinobacteria, Bacteroidetes, and Firmicutes [13, 28]. 
Out of these four predominant phyla, 31·1% are phylum Firmicutes, particularly 
families Bacillaceae, 15.7%, and Clostridiaceae, 11·4%. [28]. Proteobacteria occu-
pies 29.5% of GM species isolated in humans, with 20% belonging to the family 
Enterobacteriaceae. Phylum Actinobacteria constitutes 25·9% of the GM isolated in 
humans, with 24·2% identifies as family Mycobacteriaceae. Bacteroidetes amount to  
7·1% of the total species cultured from humans, and 29% of the phylum belongs 
to the family Prevotellaceae [15]. About 386 of the isolated species were identified 
to be anaerobic. Such microbiota would be found in the oral cavity and GIT – the 
mucosal regions [13].
3.1 Proteobacteria
Proteobacteria (PBAC) was initially called purple bacteria because of their red-
dish pigmentation, Figure 2. In 1988, a group of scientists studied the purple bacteria 
and their relatives. The scientists discovered that most of the bacteria and their rela-
tives were neither purple nor photosynthetic. However, the bacteria group had great 
biological significance through physiological features. Therefore, scientists named 
these groups of microorganisms PBAC [31, 33, 34]. Characteristics of PBAC are:
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• The PBAC is gram-negative bacteria with an outer membrane made up of 
lipopolysaccharides. This outer membrane makes them resistant to drugs, 
particularly antibiotics [34, 35].
• The PBAC classes, families, and genera differ in motion and metabolic activi-
ties. They have different shapes. Some have flagella, some are non-motile, 
while some perform bacteria gliding [34, 35].
• The PBAC is facultative or obligatory anaerobic. They can be chemoautotrophs 
or heterotrophic, and they are pathogens [34, 35].
• Some classes and genera are of considerable importance to medical experts, 
food industries, and scientists within this phylum. Class Gammaproteobacteria 
includes important pathogens, Salmonella, Vibrio, Pseudomonas, Escherichia, 
and Yersinia. Genera such as Helicobacter and Campylobacter from class 
Epsilonproteobacteria are common in the GIT [34].
• Proteobacteria are allied to inflammation; therefore, their population increases 
in the gut in a condition prone to inflammation [31, 36].
3.2 Actinobacteria
Actinobacteria (ABAC), another populous bacteria in the human gut, are gram-
negative bacteria and are mainly aerobic, even though some can survive under 
anaerobic conditions [37, 38]. The ABAC has other characteristics;
• The DNA of ABAC contains a high level of Guanine and Cytosine [37].
• Even though there are several genera, the pathogens that live in humans 
include Mycobacterium, Corynebacterium, Nocardia, and some species of 
Streptomyces [37, 38].
• The ABAC are secondary producers of metabolites; therefore, they are 
of interest for pharmacological and commercial purposes. The subclass 
Actinobacteridae and the order Actinomycetales are particularly of medical 
and economic benefit because their metabolites have antibiotics, particularly 
the genus Streptomyces [37, 38] (Figure 3).
Figure 2. 
Proteobacteria are called purple bacteria because of reddish pigmentation [32].
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3.3 Firmicutes
Firmicutes are gram-positive bacteria, though some have a pseudo outer 
membrane that makes them stain gram-negative [35, 40]. Phylum Firmicutes 
is notable for microorganisms that profer health benefits. Some genera of 
Firmicutes are administered as probiotics to profer gut health benefits. 
Characteristics include;
Firmicutes could be round (cocci) or rod-like (bacillus) in shape. Unlike the 
ABAC, they have a low level of Guanine and Cytosine in their DNA; they are acid-
tolerant and take part in metabolic and physiological activities [35, 40].
There are two major classes; the anaerobic Clostridia and the obligate or faculta-
tive aerobic Bacilli [35, 40]. These are notable pathogens and beneficial microorgan-
isms within this phylum. One crucial order of this phylum is the Lactobacillales 
(Lactic Acid Bacteria). Lactic acid bacteria produce lactic acid as a metabolite 
during glucose fermentation. Lactic Acid Bacteria appear everywhere in the food 
and are therefore regarded safe for consumption. In addition, they are known to 
contribute health benefits to the human gut [35, 40].
The genera for Lactic Acid Bacteria include Lactococcus, Enterococcus, and 
Streptococcus. The genus Lactobacillus (Figure 4) is the most common microbe 
used as probiotics [35, 40]. Firmicutes are either anaerobic, particularly 
Clostridia, while class Bacilli is an obligate or facultative aerobe. Therefore, 
bacteria belonging to class Bacilli would not grow or populate in an anaerobic 
environment [35, 40].
3.4 Bacteroidetes
Bacteroidetes are gram-negative, non-spore-forming, and anaerobic bacteria 
[42]. Bacteroidetes can survive in several environments, including the gut and 
skin. The class Bacteroidia is the most studied class of this phylum GM [42]. One 
common genus in this class is the Bacteroides. Bacteroides are clinically signifi-
cant and have a mutualistic relationship with the host [42, 43]. The mutualistic 
behavior of Bacteroides occurs if they are retained in the gut. Once Bacteroides 
escape their familiar environment, they become pathogenic and can cause 
Figure 3. 
Mycobacterium tuberculosis, one of the species of Actinobacteria hosted by humans [39].
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diseases such as an abscess in different parts of the body [43]. Other features of 
Bacteroides include:
• Bacteroides break down large molecules in the human guts into simpler 
molecules, while the bacteria derive their energy source from their host. The 
bacteria hence help to produce beneficial fatty acids [42, 43].
• Bacteroides prevent other pathogens from colonizing and infecting the gut of 
the host [42].
• Bacteroides have species that are highly resistant to many antibiotics [43]
4. Short-chain fatty acid producing bacteria
The GM is a balanced environment of different microorganisms such as bacte-
ria, viruses, bacteriophages, archaea, and fungi; however, the bacteria community 
preserves the homeostasis of the gut. The bacteria community contains some 
groups of gut bacteria that produce SCFAs mentioned in Section 2.1.2. These fatty 
acids include acetate, propionate, and butyrate. The SCFAs are an essential fuel for 
the intestinal epithelial cells, and they assist the gut barrier functions and sustain 
homeostasis in the intestine [23, 44].
These groups of gut bacteria ferment indigestible dietary fibers to produce 
SCFAs. Dietary fibers such as resistant starch, inulin, wheat, oat bran, cellulose, 
pectin, and Guam gum are suitable substrates for bacteria activities and fer-
mentation. Out of all prominent bacteria phylum identified in the human body, 
the Firmicutes and Bacteroidetes are more of the SCFAs producers [23, 44]. The 
acetate and propionate are produced by phylum Bacteroidetes, while the Firmicutes 
produce more of the butyrate [23, 45]. Another genus, such as Bifidobacterium, from 
phylum Actinobacteria and some Proteobacteria, could also produce butyrate. It is 
also important to note that some butyrate producers like Bacteroides are anaerobic 
bacteria and would not be active in aerobic situations; however, class Bacilli of 
Firmicutes would thrive because they are aerobes [23, 35, 46]. The aerobic environ-
ment in a human gut will suppress the growth of some butyrate-producing bacteria 
but allow the growth of aerobic pathogens like Salmonella typhimurium [23].
Figure 4. 
Lactobacillus paracasei [41].
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4.1 Functions of short-chain fatty acids in the gastrointestinal tract
1. The SCFAs control the gene expression for energy metabolism. Butyrate, in 
particular, is the primary energy source for colon cells. Therefore, SCFAs are 
involved in the energy metabolism of colon epithelial cells [23, 47, 48].
2. Propionate act as gluconeogenesis substrate in the intestine, where it can be 
oxidized to glucose. Acetate is also available in the tissues, where it can be trans-
formed to butyrate and oxidized by muscles or used for lipogenesis [27, 49].
3. The SCFAs regulate the development of organoids. Hence, a cell proliferating 
attribute. The SCFA can induce mucus-secreting cells to secrete mucus that 
protects the mucosa [23, 48].
4. The SCFAs have been identified to suppress cancer cells or causing apoptosis to 
cancer cells. In addition, they perform the antimicrobial function because they 
can disrupt the osmotic and pH balance, creating an environment not accom-
modative to other microorganisms [48].
5. The SCFAs promote epithelial barrier function by initiating genes responsible 
for tight junctions and reforming protein, increasing epithelial resistance to 
pathogen invasion [23, 48].
6. The SCFAs induce prostaglandins which have an anti-inflammatory effect, thus 
reducing the pro-inflammatory effect. In addition, it induces anti-inflammato-
ry cytokines to reduce the inflammation of the gut, which has been attributed 
to the cause of the host’s susceptibility to some diseases [23, 49].
5. Interactions of gut microflora and diseases
The colonization of GM starts from childbirth; however, the composition 
starts changing based on different factors. For example, the birth delivery 
method, the mode of feeding, and the type of food offered to an infant determine 
GM’s population [14, 22, 50]. For example, researchers reported that the type 
of bacteria composition in children fed with breast milk differs from children 
fed with the formula [14, 22]. In the same way, children born via natural birth 
have different GM compositions from children born via assisted delivery, such as 
caesarian surgery [14, 22]. As infants are introduced to solid food, GM composi-
tion makes another change [14, 22]. It is also important to note that the composi-
tion of GM also differs based on the part of GIT. For instance, the types of GM in 
the colon are different from the types in the stomach. This difference is because 
of factors such as the redox condition of the different organs. Other factors are 
the pH of the organ environment, allergies, the motility of organs, secretions in 
each organ such as the gastric acid secretion of the stomach, and the undamaged 
ileocaecal valve [14, 22]. Bacteria colonizing the guts from birth are also referred 
to as commensal bacteria because they benefit the host [14, 51]. For instance, 
Bacteroidetes and Firmicutes are the major phyla involved in breaking down 
macromolecules into simpler forms, particularly the indigestible fibers. However, 
abnormal changes can occur to the GM, leading to an abnormal composition of 
bacteria. This condition can be the onset of chronic diseases such as type 1 and 
2 diabetes, obesity, cardiovascular diseases, cancer, and inflammatory bowel 
diseases [14, 52].
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Surprisingly, abnormal bacteria composition has been linked with diseases that 
are considered temporary due to physiological changes like metabolic and immu-
nological changes [7, 53]. An example is a gestational diabetes. During pregnancy, 
some women who cannot produce enough insulin develop gestational diabetes. The 
physiological changes occurring during pregnancy, such as weight gain, reduce  
the effective use of insulin, resulting in insulin resistance, as shown in Figure 5. The 
development of insulin resistance makes the body of the pregnant woman demands 
more insulin production. Even though gestational diabetes occurs late in pregnancy, 
some women experience insulin resistance before pregnancy [53, 55]. Women with 
gestational diabetes, if not well managed, might have their unborn babies at risk 
of being over 9lbs weight birth, which could bring delivery hazards to the mother. 
Also, the baby might be born earlier than anticipated, which could cause health 
problems for the baby. In addition, the baby might be born with low blood sugar. 
Women who have gestational diabetes are equally at a 40% risk of developing type 
2 diabetes. About 5 to 20% of all world pregnancies are affected by gestational dia-
betes, and the percentage is increasing [7, 53, 56]. These statistics suggest a possible 
increase in people at risk of developing or living with type 2 diabetes, one of the 
world’s major chronic diseases. Changes in the GM population are noticed in people 
who have gestational diabetes and chronic diseases. This change in population is the 
gut dysbiosis.
5.1 Gut dysbiosis
Gut dysbiosis is a condition in which there is a change in the balance of GM 
composition. Some phyla become highly populated while some reduce in popula-
tion. This condition creates abnormality in the human GIT, and the pathogenesis of 
commensals bacteria starts [52]. Most bacteria in the gut are beneficial; however, 
when the balance in population changes in these bacteria gut colonies, as shown 
in Figure 6, dysbiosis occurs [7, 52]. Some symptoms of dysbiosis are mild and 
temporary; however, leaving dysbiosis untreated could result in severe symptoms 
associated with chronic diseases [52]. Even though commensals bacteria antago-
nize invading microorganisms, sometimes foreign microorganisms can seize the 
epithelium and overthrow the commensals, destabilizing the immune response 
[52]. After that, the invading pathogens induce inflammation to which they would 
be resistant, facilitating their growth and changing the balance of commensals 
bacteria. Viruses create series of mechanisms that regulate the activities of the 
Figure 5. 
Insulin resistance during gestational diabetes [54].
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commensals, making them harmful to the host [16, 58]. Factors causing dysbiosis 
include a dietary change, chemical consumption like insecticides, alcoholism, 
improper use of medications, particularly antibiotics, poor dental hygiene, unpro-
tected sex, stress, and anxiety, psychological stress. All these factors could change 
the balance of GM. In addition, the genotype and immune metabolic functions can 
alter the population of commensal microbes [52, 59, 60].
Symptoms of dysbiosis are dependent on the location of GM imbalance devel-
opment and the types of bacteria involved. Symptoms could be gas, bloating, 
diarrhea, constipation, and cramps [52, 61]. To determine the imbalance of GM, 
most researchers make use of a human stool [52, 62]. The collected sample is then 
tested to determine the type of bacteria in the host’s body. The organic acid test is 
another test used medically to determine imbalance [52, 62]. Some bacteria produce 
organic acids as metabolites. Therefore, the concentration of the organic acid in the 
urine sample determines the host’s bacteria population. The hydrogen breath test is 
another test conducted to determine dysbiosis. In this case, gases from the mouth 
are tested for imbalance [52, 62]. Unfortunately, diseases tolerance varies in people; 
not everyone with dysbiosis shows severe symptoms that call for urgent attention 
or medical checkup, particularly at a young age. Ignoring or leaving the dysbiosis 
untreated, however, can result in many severe diseases.
5.2 Diseases associated with dysbiosis
The GM is partly responsible for the physiology of the body systems. Changes in 
the balance or population of GM have been linked to bowel diseases, allergies, and 
chronic metabolic diseases such as diabetes, obesity, cardiovascular diseases, and 
short-term disease like gestational diabetes.
5.2.1 Type 1 diabetes
According to research, Firmicutes such as Lactobacillus, Actinobacteria 
such as Bifidobacterium decreased in populations in children diagnosed with 
type 1 diabetes. In contrast, the population of Firmicutes such as Clostridium 
and Veillonella, Bacteroidetes like Bacteroides and Prevotella increased [14, 15]. 
Patients with Type 1 diabetes had low butyrate-producing and mucin degrad-
ing microbes, while pathogenic bacteria increased in population in the gut. 
Butyrate-producing bacteria and mucin degrading microbes are good for gut 
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in Section 4.1. Mucin degradation releases complex carbohydrates and produces 
SCFAs like acetate and propionate [64].
5.2.2 Type 2 diabetes
In patients with type 2 diabetes, Clostridia and Bacilli Firmicutes decreased 
in population while PBAC increased. Butyrate-producing microorganisms like 
Firmicutes are known to produce SCFAs. In addition, butyrate has the energy that 
provides 5–15% of the calories needed per individual daily [47, 65]. Therefore, 
Firmicutes’ absence or reduced population in type 2 diabetes could elevate the blood 
glucose level. The increase in blood glucose is because the host will seek the missing 
calories by consuming more food. Lack or low butyrate concentration could also 
reduce satiety, making the host eat more, thus raising blood glucose [30, 47, 66].
Proteobacteria, which are more dominant in type 2 diabetes, induce inflamma-
tory responses [36, 47]. An alteration in PBAC composition is common in metabolic 
syndromes causing diseases. In a study where the fecal samples of patients with 
type 2 diabetes were analyzed, a significant number of Enterobacteriaceae, a family 
from the phylum PBAC, were found [14, 31]. At the initiation of an inflammatory 
response, specific proteins are released into the bloodstream. These proteins inhibit 
insulin secretion and build insulin resistance in the body [14, 67].
5.2.3 Gestational diabetes
The profile of GM in women with gestational diabetes is similar to patients 
who have type 2 diabetes [53, 68]. In a study to determine the onset of dysbiosis 
in pregnant women, GM was typical in pregnant women in their first semester 
trimester. However, by the third trimester, the population of Proteobacteria 
and Actinobacteria increased while butyrate-producing microorganisms like 
Faecalibacterium and Eubacterium from phylum Firmicutes reduced. In addition, 
the Enterobacteriaceae family and Streptococcus were also numerous. Even though 
scientists observed Bacteroidetes and Firmicutes throughout all three trimesters 
of the pregnancy [68, 69]; however, the strong negative relationship between 
Bacteroidetes and Firmicutes phyla in healthy pregnant women was missing in 
women with gestational diabetes [7].
Most of the GM reduced were SCFA producing bacteria. The absence of these 
bacteria in pregnant women reduced the physiological function of the intestine. The 
gut permeability was not regulated, insulin sensitivity was reduced, inflammatory 
response that can lessen the development of diabetes was equally reduced [7]. Gut 
dysbiosis could be a biomarker for gestational diabetes, and a test of dysbiosis could 
be early detection before the pregnancy reaches the third trimester [7]. Changes in the 
GM population was associated with diet and weight gain during pregnancy [53, 68].
5.2.4 Inflammatory bowel disease
The two major bowel diseases associated with dysbiosis are Crohn’s disease and 
ulcerative colitis [14, 15, 23]. In patients with Crohn’s disease, the composition of 
GM was different from healthy individuals. Bacteria belonging to Firmicutes and 
Actinobacteria were decreased, some of which had a probiotic effect, while PBAC 
and Ruminococcus gnavus, another Firmicutes associated with inflammation, were 
increased [14, 24, 31, 70]. Increased susceptibility to Crohn’s disease is attributed 
to a lack of the production of SCFAs. The PBAC is signaled as a pointer to instabil-
ity in the microbiota. Therefore, an increase in the PBAC population is found in 
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people with IBD disease. Even though the exact reason for the increase in PBAC is 
unknown, it is hypothesized that PBAC, with its inflammatory effect, creates anaer-
obic conditions in the gut. The beta-oxidation process reduces when proinflam-
mation occurs. Therefore, anaerobic conditions contribute to the growth of PBAC, 
which are facultative anaerobe, thereby allowing dysbiosis [14, 15]. Anaerobic 
conditions increase the growth of pathogenic Firmicutes but reduce the population 
of the beneficial Firmicutes, like the Lactic Acid Bacteria [35, 40]. Another IBD 
due to dysbiosis is ulcerative colitis [14, 15]. Scientists discovered that Lactobacilli 
were low in composition in patients with ulcerative colitis at an active stage, while 
the Clostridiales order of Firmicutes was more prominent. High Escherichia coli was 
equally identified in people with active ulcerative colitis. Inflammation seen in IBD 
is associated with the decreased colonization resistance [14, 15].
Inflammatory Bowel Diseases (IBD) occur when genetic and environmental 
factors encourage the growth of pathogens that can decrease the population of 
commensals, thereby causing inflammation [15]. In addition, IBD can occur when 
there is an unusual immune response against commensal bacteria. For example, 
sometimes immune cells such as macrophages could not recognize GM and trigger 
an immune response which attacks the intestinal wall [15]. Hence, Firmicutes and 
Bacteroidetes decrease while PBAC increases.
5.2.5 Obesity
When the GM composition of healthy and patients with obesity were compared, 
anaerobic Firmicutes and Proteobacteria were increased in the fecal samples of 
patients. At the same time, Bacteroidetes decreased compared to a healthy individ-
ual. The high ratio of Firmicutes and Bacteroidetes has been linked to obesity [14, 
71]. A significant increase in Enterobacteriaceae, PBAC family, was equally found in 
patients with obesity. This population of PBAC family reduced after the patient lost 
weight [31]. In a study on mice, a toll-like receptor 5, a sensor that detects microbial 
infection to initiate an immune response, was deficient when fed with a high-fat 
diet. The masking of toll-like receptor 5 concealed the changes occurring in the GM, 
and the body could not produce an immune response to fight the strange invading 
organisms [51, 72]. Deficiency of this receptor has been linked to hypertension, 
insulin resistance, and weight gain, though the exact reason for the masking was 
uncertain [15, 73].
5.2.6 Cardiovascular diseases
Microbiota dysbiosis was related to the development of cardiovascular diseases. 
A high level of PBAC was found in arteriosclerosis plaque, indicating PBAC has the 
pro-inflammatory effect that can cause plaque [15, 74]. In addition, some scientists 
reported that GM converts choline, an essential body nutrient, to trimethylamine, 
an organic compound. Trimethylamine is further processed in the liver to tri-
methylamine N-oxide which is known to increase arterial plaques. An increase 
in arterial plaque can cause arteriosclerosis diseases [14, 15]. In another study, 
Gammaproteobacteria, a class of PBAC, was connected with endogenous alcohol 
production linked to the cause of non-alcoholic fatty liver diseases, which is associ-
ated with increased risk of cardiovascular failure incidence [75].
5.2.7 Cancer
Inflammation caused by some phylum of GM could create a grave environment for 
the development and growth of cancer cells. Even though cancer linked to microbiota 
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so far occurs in body parts that house the GM, notably the GIT, the colon [15, 76]. 
Commensals sometimes take up pathogenic features when invaded, giving them 
pathogenic effects; such commensals are called pathobionts. In a study on mice, 
pathobionts and pathogens contributed to the uncontrolled epithelial cell growth of 
the colorectal region [15]. Some scientists also suggested that some GM like Bacillus 
fragilis, a Bacteroidetes are virulent and can modify the GM to favor inflammatory 
responses. These inflammatory responses could cause alterations in the epithelial 
cells, and this could result in cancer. The inflammatory response will equally allow the 
invasion of cancer allies’ microorganisms [15, 43]. In addition, people with chronic 
inflammatory disarray have been discovered to have a high susceptibility to gastric 
cancer and cancer of the lymphatic system associated with the mucosa [76].
6. Conclusion
Research continues on how GM and its activities cause chronic diseases. From 
completed studies, it is apparent that the composition of the gut differs between 
diseased and healthy individuals. While a significant population of commensals 
and SCFAs producing bacteria reduced, the pathogenic population increased and 
influenced the commensals, making them turn against the host. Pathogens equally 
created unfavorable conditions such as inflammatory or anaerobic conditions. The 
change in the environment favored the growth of pathogens but reduced the growth 
of commensals.
To take care of gut health, the types of food consumed determines the type of GM. 
Fermentable dietary fibers such as pectin, inulin, and resistant starch undergo fermen-
tation by GM to produce 15% butyrate, 60% acetate, and 25% propionate. Butyrate 
maintains colonic homeostasis and prevents inflammation, and maintains mucosal 
integrity [44], thereby playing a role in reducing dysbiosis. Therefore, food rich in 
these fermentable dietary fibers would be suitable for gut health [25, 44]. The types 
of protein consumed matter to gut health. Animal protein fermentation decreases the 
production of SCFAs, increasing the risk of IBD [25]. However, consuming plant-
based protein is associated with an increase in beneficial GM like Bifidobacterium, 
Lactobacillus, and it increases the production of SCFA [25, 44]. High consumption 
of polyunsaturated fatty acids has been associated with an increased healthy GM 
population like Lactobacillus and Roseburia, thus increasing the production of SCFA-
butyrate [25, 44]. In contrast, high consumption of sodium and food additives such as 
sweeteners are associated with changes in the composition of GM. When food is high 
in sodium, it reduces the population of commensal microorganisms like Lactobacillus. 
Also, food additives cause a significant change in the population of the balanced gut 
system [25, 44]. What humans eat can determine gut health, and the composition of 
GM in the gut contributes to overall well-being.
Asides healthy diet, there are other ways to improve gut health. One of these 
ways is the use of probiotics as supplements. Probiotics are live microorganisms 
made into pills that profer health benefits when administered in adequate amounts. 
In addition, the use of prebiotics has equally been suggested. Prebiotics are not 
microorganisms but non-digestible substances that benefit the host by improving 
the growth and activities of selected bacteria in the gut [77–79]. Other methods are 
requiring medical experts and scientists. One is fecal microbiota transplantation, 
which involves infusing stool from a healthy donor to a recipient by delivering the 
stool through the upper GIT [80]. This method requires adequate care to ensure the 
feces transferred to other patients do not have infectious microorganisms. Other 
methods being used include phage therapy, bacteria consortium transplantation, 
and the use of predatory bacteria [81].
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